
84.4% of cancer patients taking ivermectin + mebendazole for 6 months reported either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.
The largest real-world human study to date evaluating ivermectin and mebendazole in cancer patients is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.
Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” represents one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.
Read the entire article on GlobalResearch.ca …
Extensive research conducted by Dr. William Makis from “Makis Health <makisw@substack.com> on Ivermectin + Mebendazole, Ivermectin + Febendazole and othe repurposed drug combinations is available on his Substack. Continue reading this post for free in the Substack app






